Daraxonrasib extends survival in metastatic pancreatic cancer
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic ...
Tag: targeted therapy
Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy
1. The European Commission has authorized expanded venetoclax (Venclyxto) combinations for previously untreated chronic lymphocytic leukemia. 2. The approval reinforces ...
New targeted therapy daraxonrasib improves survival in pancreatic cancer
1. Daraxonrasib significantly improves survival in metastatic pancreatic cancer compared with standard chemotherapy. 2. Strong response rates in combination therapy ...
Selpercatinib vs Chemotherapy and Pembrolizumab in RET Positive NSCLC
1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ± ...
Adavosertib compared with active monitoring is potentially effective against TP53/RAS-mutant metastatic colorectal cancer.
1. Patients on adavosertib had both increased progression-free survival and better tumor control, as compared to patients being actively monitored ...
#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors
1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such ...
